American Society of Hematology

Figure 1

$Figure 1. Aberrant NK cell frequency and NK cell CD16 expression in MDS PBMCs. (A-C) PBMCs from normal donors and MDS patients were stained with anti-CD56, anti-CD3, and anti-CD16 mAbs. (A-B) Gating strategy for the evaluation of the lymphocyte populations in normal donors (A) and MDS patients (B). Plots are representative from 1 normal donor (#12 of 20) and 1 higher-risk MDS patient (#49 of 67), and gate frequency indicates population percent normalized to the all-cell fraction based on the forward scatter (FSC)/side scatter (SSC) gate excluding debris. (C) Percent of CD56−/CD3+ T cells and CD56+/CD3− NK cells (normalized to all-cell fraction based on the FSC/SSC gate excluding debris) and (D) percent of CD16+ NK cells (calculated as the percent of CD56+/CD3− NK cells) and mean fluorescence intensity of CD16 expression on NK cells were determined by fluorescence-activated cell sorter (FACS) analysis (****P < .0001). ECD, energy-coupled dye.$

Aberrant NK cell frequency and NK cell CD16 expression in MDS PBMCs. (A-C) PBMCs from normal donors and MDS patients were stained with anti-CD56, anti-CD3, and anti-CD16 mAbs. (A-B) Gating strategy for the evaluation of the lymphocyte populations in normal donors (A) and MDS patients (B). Plots are representative from 1 normal donor (#12 of 20) and 1 higher-risk MDS patient (#49 of 67), and gate frequency indicates population percent normalized to the all-cell fraction based on the forward scatter (FSC)/side scatter (SSC) gate excluding debris. (C) Percent of CD56⁻/CD3⁺ T cells and CD56⁺/CD3⁻ NK cells (normalized to all-cell fraction based on the FSC/SSC gate excluding debris) and (D) percent of CD16⁺ NK cells (calculated as the percent of CD56⁺/CD3⁻ NK cells) and mean fluorescence intensity of CD16 expression on NK cells were determined by fluorescence-activated cell sorter (FACS) analysis (****P < .0001). ECD, energy-coupled dye.

This Feature Is Available To Subscribers Only